[MiR-4772 Modulates Tumor Immune Microenvironment by Regulating Immune- Related Genes in Ovarian Cancer]

Overview

Journal Nan Fang Yi Ke Da Xue Xue Bao

Specialty General Medicine

Date 2022 Dec 12

PMID 36504056

Authors

A Zhao

Y Su

D Fu

Affiliations

Soon will be listed here.

Abstract

Objective: To explore the regulatory role of miR-4772 in the formation of tumor immune microenvironment in ovarian cancer.

Methods: The optimal cutoff level of PD-L1 expression was calculated based on data from 294 ovarian cancer patients in the TCGA database. The differentially expressed genes (DEGs) between high and low PD-L1 expression groups were screened, and the important DEGs were identified by correlation analysis. WGCNA analysis was performed to select the weighted genes and PD-L1-related miRNAs, from which the hub genes were obtained by intersection analysis. ssGSEA analysis was used to evaluate the effect of PD-L1 and miR-4772 expressions on the tumor immune microenvironment in ovarian cancer. KEGG analysis was used to identify the involved signal pathways, and the interactions between the hub genes were mapped by protein-protein interaction (PPI) analysis. Survival analysis was carried out to identify the survival-related hub genes, and the results were validated using the data of 399 patients with ovarian cancer from GEO database and the sequencing results of SKOV3 cells transfected with miR-4772 mimics or inhibitor.

Results: According the optimal cutoff level of PD-L1 expression of 1.31582 (90th quantile), the patients were divided into high- and low-PD-L1 expression groups. A total of 840 DEGs were identified, including 549 significantly up-regulated genes and 291 down-regulated genes. Among them, 20 important DEGs were found to closely correlate with miR-4772 expression, and WGCNA analysis identified 48 weighted genes significantly correlated with miR-4772. Twelve genes were identified as both key DEGs and weighted genes and were treated as the hub genes. ssGSEA analysis showed that both the patients with high PD-L1 expressions and those with high miR-4772 expressions showed more active immune infiltration and functional activity. The 12 hub genes were involved mainly in immune-related signaling pathways, and PPI analysis suggested significant interactions among the hub genes. The two hub genes CD96 and TBX21 showed close correlation with the survival of ovarian cancer patients. The sequencing results of SKOV3 cells transfected with miR-4772 mimics or inhibitor showed that the changes in miR-4772 expression level caused obvious changes in the expressions of the 12 hub genes and PD-L1.

Conclusion: MiR-4772 plays a regulatory role in the formation of tumor immune microenvironment in ovarian cancer by regulating 12 hub genes.

Citing Articles

Pan-cancer analysis and single-cell analysis reveals FAM110B as a potential target for survival and immunotherapy.

Li Y, Li X, Wu B, Su S, Su Y, Guo L Front Mol Biosci. 2024; 11:1424104.

PMID: 39170745 PMC: 11335499. DOI: 10.3389/fmolb.2024.1424104.

References

Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121. DOI: 10.1056/NEJMoa1809615. View

Yu D, Lim J, Wang X, Liang F, Xiao G . Enhanced construction of gene regulatory networks using hub gene information. BMC Bioinformatics. 2017; 18(1):186. PMC: 5364645. DOI: 10.1186/s12859-017-1576-1. View

Shi T, Morishita A, Kobara H, Masaki T . The Role of Long Non-Coding RNA and microRNA Networks in Hepatocellular Carcinoma and Its Tumor Microenvironment. Int J Mol Sci. 2021; 22(19). PMC: 8508708. DOI: 10.3390/ijms221910630. View

Wang F, Tao Z, Tian Z, Jin J, Dong J, Dai Y . CCR5 as a Prognostic Factor in Lower-Grade Glioma is Involved in the Remodeling of the Tumor Microenvironment. Front Genet. 2022; 13:874896. PMC: 9294513. DOI: 10.3389/fgene.2022.874896. View

Yoneda K, Kuwata T, Kanayama M, Mori M, Kawanami T, Yatera K . Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer. Br J Cancer. 2019; 121(6):490-496. PMC: 6738061. DOI: 10.1038/s41416-019-0541-3. View

Feng S, Sun H, Zhu W . MiR-92 overexpression suppresses immune cell function in ovarian cancer via LATS2/YAP1/PD-L1 pathway. Clin Transl Oncol. 2020; 23(3):450-458. DOI: 10.1007/s12094-020-02439-y. View

Zhang J, Wang H, Yuan C, Wu J, Xu J, Chen S . ITGAL as a Prognostic Biomarker Correlated With Immune Infiltrates in Gastric Cancer. Front Cell Dev Biol. 2022; 10:808212. PMC: 8987306. DOI: 10.3389/fcell.2022.808212. View

Duan M, Fang M, Wang C, Wang H, Li M . LncRNA EMX2OS Induces Proliferation, Invasion and Sphere Formation of Ovarian Cancer Cells via Regulating the miR-654-3p/AKT3/PD-L1 Axis. Cancer Manag Res. 2020; 12:2141-2154. PMC: 7102881. DOI: 10.2147/CMAR.S229013. View

Zuo Y, Zheng W, Tang Q, Liu J, Wang S, Xin C . miR‑576‑3p overexpression enhances cisplatin sensitivity of ovarian cancer cells by dysregulating PD‑L1 and cyclin D1. Mol Med Rep. 2020; 23(1). DOI: 10.3892/mmr.2020.11719. View

10.

Li J, Bi L, Shi Z, Sun Y, Lin Y, Shao H . RNA-Seq analysis of non-small cell lung cancer in female never-smokers reveals candidate cancer-associated long non-coding RNAs. Pathol Res Pract. 2016; 212(6):549-54. DOI: 10.1016/j.prp.2016.03.006. View

11.

Breuning J, Brown M . T Cell Costimulation by CD6 Is Dependent on Bivalent Binding of a GADS/SLP-76 Complex. Mol Cell Biol. 2017; 37(11). PMC: 5440646. DOI: 10.1128/MCB.00071-17. View

12.

Hu Z, Xue C, Zheng J, Lu X, Li J, Dong H . Hyper-Methylated Hub Genes of T-Cell Receptor Signaling Predict a Poor Clinical Outcome in Lung Adenocarcinoma. J Oncol. 2022; 2022:5426887. PMC: 9007647. DOI: 10.1155/2022/5426887. View

13.

Sheng Q, Zhang Y, Wang Z, Ding J, Song Y, Zhao W . Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells. Clin Exp Immunol. 2019; 200(1):45-52. PMC: 7066384. DOI: 10.1111/cei.13406. View

14.

Andersen M, Schrama D, Straten P, Becker J . Cytotoxic T cells. J Invest Dermatol. 2006; 126(1):32-41. DOI: 10.1038/sj.jid.5700001. View

15.

Nasarre P, Bonilla I, Metcalf J, Hilliard E, Klauber-DeMore N . TRAF3-interacting protein 3, a new oncotarget, promotes tumor growth in melanoma. Melanoma Res. 2018; 28(3):185-194. DOI: 10.1097/CMR.0000000000000440. View

16.

Yamamoto S, Kato K . Pembrolizumab for the treatment of esophageal cancer. Expert Opin Biol Ther. 2020; 20(10):1143-1150. DOI: 10.1080/14712598.2020.1792881. View

17.

Maia J, Caja S, Moraes M, Couto N, Costa-Silva B . Exosome-Based Cell-Cell Communication in the Tumor Microenvironment. Front Cell Dev Biol. 2018; 6:18. PMC: 5826063. DOI: 10.3389/fcell.2018.00018. View

18.

Huo Y, Zhang K, Han S, Feng Y, Bao Y . Lymphocyte cytosolic protein 2 is a novel prognostic marker in lung adenocarcinoma. J Int Med Res. 2021; 49(11):3000605211059681. PMC: 8649447. DOI: 10.1177/03000605211059681. View

19.

Feng M, Wu Z, Zhou Y, Wei Z, Tian E, Mei S . BCL9 regulates CD226 and CD96 checkpoints in CD8 T cells to improve PD-1 response in cancer. Signal Transduct Target Ther. 2021; 6(1):313. PMC: 8379253. DOI: 10.1038/s41392-021-00730-0. View

20.

Chen S, Gao C, Yu T, Qu Y, Xiao G, Huang Z . Bioinformatics Analysis of a Prognostic miRNA Signature and Potential Key Genes in Pancreatic Cancer. Front Oncol. 2021; 11:641289. PMC: 8174116. DOI: 10.3389/fonc.2021.641289. View